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Abstract
Background: Hereditary coproporphyria (HCPO) is a low-penetrance, autosomal dominant, acute hepatic porphyria characterized by the overproduction and
excretion of coproporphyrin. The most common neurological manifestations of this entity include peripheral, predominantly motor dysfunction, and central
nervous system dysfunction. Ataxia associated with HCPO has not been reported previously. The aim of this article is to report a patient with HCPO presenting
with acute ataxia.
Case Report: We describe a 44-year-old patient presenting clinically with acute ataxia who was diagnosed with HCPO; mutations were analyzed in the
coproporphyrin-oxidase III (CPOX) gene in the patient and in six asymptomatic first-degree relatives.
Discussion: The patient was heterozygous for a mutation causing the amino acid exchange Q306X in the CPOX gene. No relatives carried the same or another
mutation in the CPOX gene. HCPO should be considered in the differential diagnosis for patients presenting with ataxia.
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Introduction
Porphyrias are metabolic diseases that develop from either inherited
or, more infrequently, acquired disturbances of heme biosynthesis,
leading to an overproduction of heme precursors in liver and bone
marrow. Porphyrias are divided into acute hepatic, chronic hepatic,
and erythropoietic types depending on the main site of expression of
the enzymatic defect. Eight enzymes are involved in the eight steps of
heme biosynthesis, and deficiencies in seven of them (except the delta-
aminolevulinic synthase, responsible for the first step) each correlate
with a specific form of porphyria.1,2
Patients suffering from acute porphyrias share a common clinical
symptom of acute, severe abdominal pain attacks. In addition,
symptoms such as nausea, vomiting, hypertension, tachycardia, and
hyponatremia are present in most porphyric crises. Severe or
prolonged attacks are accompanied by peripheral, predominantly
motor dysfunction, and central nervous system dysfunction.3 The
presence of light-induced skin symptoms due to the dermal accumu-
lation of the photosensitizing porphyrins, mainly blisters, ulcers, and
skin fragility, are common in some acute porphyrias.3
Hereditary coproporphyria is a low-penetrance, autosomal domi-
nant, acute hepatic porphyria characterized by the overproduction
and excretion of coproporphyrin. The disease is the result of deficient
activity of the mitochondrial enzyme coproporphyrinogen oxidase
(CPOX, EC1.3.3.3) as a consequence of the inheritance of mutations
in the CPOX gene (chromosome 3q12; OMIM 612732, gene ID 1371).
In most cases, enzyme activity is reduced to nearly 50% in
heterozygotes. Clinical crises are characterized by an acute poly-
symptomatic syndrome with abdominal, cardiovascular, neurological,
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and psychiatric symptoms; nearly 20% of patients may experience
photosensitivity.1,3,4 At least 36 different mutations in the CPOX gene,
with a high proportion of missense mutations, have been described.5–7
We report a patient who was diagnosed with hereditary copropor-
phyria associated with a mutation in the CPOX gene presenting with
acute ataxia.
Case report
The propositus was a 44-year-old male. He was a heavy smoker (60
cigarettes per day) and a moderate ethanol consumer, but had no other
medical antecedents of interest. He did not consume drugs or herbal.
He was admitted to the hospital for sudden onset of dizziness, severe
gait unsteadiness, and difficulty with speech. The previous day he had
been painting a metallic staircase with red lead paint. General
examination revealed no abnormalities. Neurological examination
showed scanning speech (considerably slow and dysarthric speech with
pronounced slurring, most words being understandable), a mild
vertical skew deviation of eyes without nystagmus, severe gait and
trunk ataxia (the patient could only walk assisted by another person,
gait speed was extremely low, he was unable to stand with feet together
but was able to stand in a natural position with considerable sway and
corrections, and he had moderate oscillations of the trunk and legs
while sitting), mild dysmetria, and mild action tremor in the finger-to-
nose and the finger-to-finger tests; moderate dysmetria and mild action
tremor in the heel-to-knee test, and moderate dysdiadochokinesia for
pronation supination alternating movements. The basal scores of the
International Cooperative Ataxia Rating Scale (ICARS)8 are given in
Table 1.
Blood count, routine biochemistry; copper and iron metabolism
studies; and serum levels of thyroid hormones, vitamins A, B1, B6, B12,
E, folic acid, proteinogram, immunoglobulins, C3, and C4 were
normal. Serological studies for syphilis; Brucella; Borrelia; hepatitis A,
B, and C; HIV, herpesvirus simplex 1 and 2, herpesvirus zoster;
cytomegalovirus; Epstein–Barr virus; and measles were negative.
Antinuclear antibodies, anti-Sjo¨gren syndrome A and B, antineutro-
phil cytoplasmic, antigliadin antibodies, and cryoglobulins were
negative. Tumor markers, including carcinogenic embryogenic anti-
gen; alpha-fetoprotein; carbohydrate antigen (CA)125, CA19-9, and
CA15-3; neuron-specific enolase; and prostatic-specific antigen were
negative. Anti-Yo and anti-Hu antigens were negative both in serum
and in cerebrospinal fluid (CSF). A test for 14-3-3 protein in CSF was
also negative.
Brain computed tomography (CT) scan, brain magnetic resonance
imaging, and thoraco-abdomino-pelvic CT scan were normal. Routine
CSF analysis showed no abnormalities. Electromyography and nerve
conduction studies were normal. Molecular genetic studies for
Friedreich’s ataxia; spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, 12,
and 17; and dentate-rubro-pallido-luysian atrophy were negative.
Serum levels and 24-hour urinary excretion of lead were normal. The
measurement of urinary excretion of porphyrins and their precursors
showed a marked increase in excretion of coproporphyrins (1478 mg/
24 hours; normal values 0.0–160.0 mg/24 hours) and total porphyrins
(1616 mg/24 hours, normal values 0.0–200.0 mg/ 24 hours), a mod-
erate increase in uroporphyrin excretion (138 mg/24 hours, normal
values 0.0–60.0 mg/24 hours), a mild increase in excretion of
porphobilinogen (2.53 mg/24 hours, normal values 0.0–2.0 mg/
24 hours), and decreased concentration of delta-aminolevulinic acid
(0.12 mg/g of creatinine; normal values 1.0–7.0 mg/g of creatinine).
The patient was treated with intravenous heme arginate
(Normosang, 250 mg per day) for 10 days. This treatment led to a
moderate clinical improvement of ataxia as assessed with ICARS8
(pre- and post-treatment scores, 15 days after the onset of the
treatment, are given in Table 1) and normalized values of urinary
excretion of coproporphyrins (155 mg/24 hours), uroporphyrins
(30 mg/24 hours), and total porphyrins (195 mg/24 hours). Two
months later, the patient developed a severe behavioral disorder with
aggressiveness, which resulted in divorce, and follow-up was lost.
We investigated the presence of mutations in all CPOX gene exons in
the propositus: his mother aged 76 years (the father was deceased); one
of his two brothers, aged 47 years; and his four sons, aged 11, 9, 7, and
5 years. All the relatives of the propositus were asymptomatic and
provided written informed consent to this analysis (in the case of the
children, written informed consent was provided by their mother).
DNA was isolated from peripheral lymphocytes. Sequencing
analysis was performed as follows: first, fragments comprising the
whole exon and the 59- and 39- flanking regions were amplified using
the primers described in Table 2, then amplified fragments were
analyzed by direct sequencing as described elsewhere.9 Sequencing
analyses were repeated in triplicate. Details for amplification
conditions and oligonucleotides utilized for sequencing analyses are
available on request.
The propositus was heterozygous for the mutation causing the
amino acid exchange Q306X (exon 4) described elsewhere.7 None of
the patient’s relatives had CPOX gene mutations.
Discussion
Our patient presented with acute ataxia following exposure to
industrial red lead paint. Etiological studies on possible causes of
hereditary or acquired ataxias were negative. However, because urine
analysis showed a marked excretion of coproporphyrins and of total
porphyrins, the patient was diagnosed with hereditary coproporphyria.
This clinical entity is considered a very rare disease in Spain, where to
our knowledge only six cases have been reported to date.6,10,11 The
rationale of testing this patient for porphyria was the exposure of the
patient to red lead paint, which could act as a trigger of acute
porphyria.12,13
Although we cannot rule out the association of ataxia and bioche-
mical features of hereditary coproporphyria in our patient as
coincidental, the clinical improvement of ataxia after treatment with
heme arginate (together with improvement in biochemical parameters)
seems to support this association. Prior to the development of ataxia,
our patient had never suffered from recurrent abdominal pain or
experience any skin or cardiovascular symptoms or symptoms
suggesting peripheral or central nervous system dysfunction.
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Table 1. Scores of the International Cooperative Ataxia Rating Scale (ICARS) before Treatment with Heme Arginate and 2 Weeks After Treatment






Walking capacities 7/8 5/8
Gait speed 3/4 2/4
Standing capacities, eyes open 4/6 3/6
Spread of feet in natural position
without support, eyes open
3/4 2/4
Body sway with feet together, eyes
open
3/4 2/4
Body sway with feet together, eyes
closed
3/4 2/4
Quality of sitting position 2/4 1/4
Posture and gait score (static score) 25/34 17/34
Kinetic function Knee-tibia test 6/8 2/8
Action tremor in the heel-to-knee test 2/8 2/8
Finger-to-nose test: decomposition and
dysmetria
4/8 2/8
Finger-to-nose test: intention tremor of
the finger
2/8 2/8






Drawing of the Archimedes spiral on a
pre-drawn pattern
2/4 2/4
Kinetic score (limb coordination) 24/52 14/52
Speech disorders Dysarthria: fluency of speech 3/4 1/4
Dysarthria: clarity of speech 2/4 1/4
Dysarthria score 5/8 2/8
Oculomotor
disorders
Gaze-evoked nystagmus 0/3 0/3
Abnormalities of the ocular pursuit 1/2 1/2
Dysmetria of the saccade 1/1 1/1
Oculomotor movement score 2/6 2/6
Total ataxia score 56/100 35/100
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The mutations analysis performed on the patient and his asymp-
tomatic first-degree relatives revealed that he was the only member of
the family who had a previously reported mutation in the CPOX gene
(Q306X).7 To our knowledge, the presentation of hereditary copropor-
phyria with acute ataxia has not been reported. The possibility that
this symptom could be related to the presence of the Q306X mutation
is unclear. Urinary analysis of porphyrins could be useful in the study
of patients with acute ataxia.
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